HiR Plus X therapy for elderly DLBCL patients who can't have chemo
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new treatment called HiR+X for older adults with a type of lymphoma (DLBCL) who cannot tolerate standard chemotherapy. It aims to offer a gentler but effective option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years or older
- You have been diagnosed with CD20-positive diffuse large B-cell lymphoma (a type of blood cancer) that has not spread to the brain or spinal cord
- You have not been treated for this lymphoma before
- Standard chemotherapy (CHOP) is not safe for you or you choose not to have it
- Your kidney and liver function are adequate based on recent blood tests
- You have at least one tumor that can be measured on scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CHiR for people 70 or older with a type of lymphoma (DLBCL) who are either too frail for standard chemo or choose not to have it. The study aims to see if this therapy can work as a gentler option.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
This study tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has not responded to treatment or has returned. The goal is to see if this combination can help control the lymphoma.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This study tests a combination of drugs (called R-mini-MCOP) in people 80 years or older with a type of lymphoma called DLBCL that has not been treated before. The goal is to see if this treatment can help control the lymphoma while being safe for older patients.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.